Revision as of 23:27, 8 January 2020

1 regimens on this page 1 variants on this page

Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.

All lines of therapy

Erlotinib monotherapy

Regimen

Study	Evidence
Hainsworth et al. 2018 (MyPathway)	Phase IIa, <20 pts in this arm

Biomarker eligibility criteria

Gene: EGFR
Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
Biomarker exclusions: EGFR exon 20 mutations

Chemotherapy

Erlotinib (Tarceva) 150 mg PO once per day

Continued indefinitely

References

MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed

@@ Line 22: / Line 22: @@
 |-
 |}
-====Eligibility criteria====
+====Biomarker eligibility criteria====
-*EGFR nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
+*Gene: EGFR
+*Alteration: nonsynonymous exon 18 or exon 21 [[Biomarkers#SNV|mutations]], or exon 19 [[Biomarkers#Deletion|deletions]]
+*Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
+*Biomarker exclusions: EGFR exon 20 [[Biomarkers#SNV|mutations]]
 ====Chemotherapy====
 *[[Erlotinib (Tarceva)]] 150 mg PO once per day

Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"